Lightstone Ventures
SelectiveFiled to raiseBoston, MAHealthcare, Biotechnology, PharmaceuticalsLast fund filed June 2021
3 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Lightstone Ventures III | June 2021 | $375M | $375M | 41 |
| Lightstone Ventures IIFiled to raise in 2017, with no closing reported yet. | 2017 | $200M | $0 | 0 |
| Lightstone Ventures | April 2013 | $250M | $165M | 30 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
5 partners are named across this firm’s filings, 3 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| Henry Plain, Jr.Not on the current fund | Slowing | Medical devices, Biotech & pharma, Climate & energy |
Classified sectors of Lightstone Ventures’s own portfolio companies, based on 30 with a verified or cited source.
| Firm | Shared boards | Companies |
|---|---|---|
| Lightstone Singapore | 26 | ACCELERON PHARMA, Apreo Health, Cala Health, Calithera Biosciences, CATABASIS PHARMACEUTICALS, CLARET MEDICAL, Cyteir Therapeutics, EarLens, ENDOGASTRIC SOLUTIONS, ExploraMed NC7, Gemini Therapeutics, GLUMETRICS, GYNESONICS, HOLAIRA, HYDRA BIOSCIENCES, Imperative Care, Kona Medical, MediSix Therapeutics, MIRAMAR LABS, MIRAMAR LABS, Moximed, PowerVision, SHOULDER INNOVATIONS, Tallac Therapeutics, Thrasos Innovation, TWELVE |
| Domain Partners | 5 | Allay Therapeutics, Kona Medical, MIRAMAR LABS, Tragara Pharmaceuticals, TWELVE |
| Versant Venture Capital | 3 |
| 9 |
| 1 |
| Michael Carusi | Slowing | Medical devices, Biotech & pharma, Digital health | 12 | 1 |
| Jason Lettmann | Quiet | Medical devices | 1 | 0 |
| Jean George | Quiet | Biotech & pharma, Healthcare services | 7 | 0 |
| Ralph ChristoffersenNot on the current fund | Quiet | Biotech & pharma | 5 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of Lightstone Ventures’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| GLUMETRICS, HOLAIRA, TWELVE |
| Abingworth Bioventures | 2 | GYNESONICS, HYDRA BIOSCIENCES |
| Aisling Capital | 2 | EarLens, PowerVision |
| Bain Capital Life Sciences | 2 | GYNESONICS, Imperative Care |
| Baird Venture Partners | 2 | Allay Therapeutics, Cala Health |
| Caduceus Capital | 2 | ACCELERON PHARMA, Gemini Therapeutics |
| NEA | 2 | ExploraMed NC7, Moximed |
| Orbimed Asia Partners | 2 | ACCELERON PHARMA, Gemini Therapeutics |
| Orbimed Genesis | 2 | ACCELERON PHARMA, Gemini Therapeutics |
| Advent Life Sciences | 1 | Moximed |
| Arboretum Ventures | 1 | Allay Therapeutics |
| Atlas Venture | 1 | Gemini Therapeutics |
| Clarus | 1 | CATABASIS PHARMACEUTICALS |
A shared board seat: a company where filings name a Lightstone Ventures partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.